|
Year:
2022 |
Month:
January
|
Volume:
11 |
Issue:
1 |
Page:
MO26 - MO29 |
Rise in Levels of Anti-SARS CoV-2
Immunoglubulin G by Covishield VaccineA Cohort Study in Rural Medical College,
West Bengal, India
|
|
Correspondence
Jayanta Kumar Rout, Sujash Biswas, Sayari Banerjee, Simit Kumar, Palash Das, Sujit Kumar Dey, Dr. Simit Kumar,
Professor, Department of Microbiology, 3rd Floor, Academic Building,
Rampurhat Government Medical College, Birbhum, West Bengal, India.
E-mail: simitkumar@gmail.com
:
|
|
Introduction: The Coronavirus Disease-2019 (COVID-19) pandemic was declared by the World Health Organisation (WHO) on 11th March 2020 caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). As a preventive measure, valid information concerning the development of antibodies is being collected for assessing the progress towards herd immunity of COVID-19.
Aim: To assess the level of Anti-SARS-CoV-2 IgG before and after vaccination by two doses of ChAdOx1 nCoV 19 vaccine in a rural Medical College of West Bengal.
Materials and Methods: The present interventional cohort study was conducted in a rural Medical College and Hospital, West Bengal, India, from February 2021 to August 2021. Total 248 willing subjects were included for this interventional study from the same socio-economic and geographical distribution depending upon a vaccine population of a rural Medical College of West Bengal. To measure the anti-SARS-CoV-2 IgG antibody authors used Indian Council of Medical Research-National Institute of Virology (ICMR-NIV) certified Anti-SARS-CoV-2 human IgG ELISA COVID KAVACH MERILISA kit and approved protocol by the ICMR.
Results: The median age of study population was 39 years (range 25-64) with 97 (39.1%) females and 151 (60.9%) males. It was found that antibody response induced by two doses of vaccination was significantly high (t-value: 28.421, p<0.001) in the vaccinated population.
Conclusion: Thus, present study suggests that vaccination may be critical to develop anti-SARS-CoV-2 IgG antibody. This would lead to a better understanding of the immunisation program and prevention of severe disease and deaths due to COVID-19.
|
|
[ FULL
TEXT ] | [ ]
|
|
Print
|
|